Home > Insider Trading > Filing (0001415889-23-002944)

Filing Details

Accession Number:: 0001415889-23-002944
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-02-21 18:12:02
Reporting Period:: 2023-02-16

Accepted Time:: 2023-02-21 18:12:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1551152	Abbvie Inc.	ABBV	Pharmaceutical Preparations (2834)	320375147

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1832571	K. Elaine Sorg	1 N. Waukegan Road North Chicago IL 60064	Svp, Us Commercial Operations	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, $0.01 Par Value	Acquisiton	2023-02-16	29,410	$0.00	47,286	No	4	A	Direct
Common Stock, $0.01 Par Value	Acquisiton	2023-02-16	6,861	$0.00	54,147	No	4	A	Direct
Common Stock, $0.01 Par Value	Acquisiton	2023-02-16	4,658	$0.00	58,805	No	4	A	Direct
Common Stock, $0.01 Par Value	Acquisiton	2023-02-16	3,874	$0.00	62,679	No	4	A	Direct
Common Stock, $0.01 Par Value	Acquisiton	2023-02-21	15,321	$105.92	78,000	No	4	M	Direct
Common Stock, $0.01 Par Value	Disposition	2023-02-21	6,901	$150.74	71,099	No	4	S	Direct
Common Stock, $0.01 Par Value	Disposition	2023-02-21	8,420	$151.29	62,679	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (Right to Buy)	Acquisiton	2023-02-16	13,166	$0.00	13,166	$149.62
Common Stock	Option (Right to Buy)	Disposition	2023-02-21	15,321	$105.92	15,321	$105.92

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,166	2024-02-16	2033-02-15	No	4	A	Direct
7,660	2022-02-18	2031-02-17	No	4	M	Direct

Footnotes

Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.12 to $151.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.12 to $151.53, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,389 on February 16, 2024, 4,389 on February 16, 2025, and 4,388 on February 16, 2026.
Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.